Literature DB >> 28723886

Prolonged viral replication and longitudinal viral dynamic differences among respiratory syncytial virus infected infants.

Monica E Brint1, Joshua M Hughes2, Aditya Shah3, Chelsea R Miller3, Lisa G Harrison1, Elizabeth A Meals1, Jacqueline Blanch1, Charlotte R Thompson3, Stephania A Cormier1, John P DeVincenzo3.   

Abstract

BackgroundLongitudinal respiratory syncytial virus (RSV) dynamics have not been well studied despite the existence of factors favoring prolonged RSV replication including high mutation rates allowing rapid evolution and potential escape from immune control. We therefore measured viral load in previously RSV-naive infants over prolonged time spans.MethodsDuring 2014-2015, quantitative nasal aspirates were collected from 51 RSV-PCR+ infants. Multiple parallel assessments of viral loads were quantified at each collected time point using a well-validated real-time quantitative reverse transcriptase polymerase chain reaction assay. After observing viral load rebound phenomenon in some infants, the viral dynamics of 27 infants with sufficient longitudinal viral load data points were analyzed using the pre-defined criteria for viral rebound. Additional analyses were performed comparing age with viral rebound, viral clearance rates, and viral load area-under-the-curve (AUCVL).ResultsThe 51 infants (303 nasal aspirate samples; mean of 5.9 per patient) exhibited slower than expected viral clearance. Lower age trended toward slower viral clearance and greater AUCVL. Six infants had detectable viral loads ≥1 month after symptom onset. Ten of twenty-seven evaluable subjects exhibited viral rebound and this rebound was age-dependent (P=0.0259). All but one rebounder were <70 days old.ConclusionInfants struggle to control primary RSV infections allowing prolonged viral replication and previously undescribed viral rebound; likely representing viral mutational immune escape.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28723886      PMCID: PMC6039969          DOI: 10.1038/pr.2017.173

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  19 in total

Review 1.  Toward primary prevention of asthma. Reviewing the evidence for early-life respiratory viral infections as modifiable risk factors to prevent childhood asthma.

Authors:  Amy S Feldman; Yuan He; Martin L Moore; Marc B Hershenson; Tina V Hartert
Journal:  Am J Respir Crit Care Med       Date:  2015-01-01       Impact factor: 21.405

Review 2.  Viral and host factors in human respiratory syncytial virus pathogenesis.

Authors:  Peter L Collins; Barney S Graham
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

3.  Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children.

Authors:  Chadi M El Saleeby; Andy J Bush; Lisa M Harrison; Jody A Aitken; John P Devincenzo
Journal:  J Infect Dis       Date:  2011-10-01       Impact factor: 5.226

4.  Effect of Preexisting Serum and Mucosal Antibody on Experimental Respiratory Syncytial Virus (RSV) Challenge and Infection of Adults.

Authors:  Bindiya Bagga; Jeffrey E Cehelsky; Akshay Vaishnaw; Tom Wilkinson; Rachel Meyers; Lisa M Harrison; Philippa L Roddam; Edward E Walsh; John P DeVincenzo
Journal:  J Infect Dis       Date:  2015-05-14       Impact factor: 5.226

5.  Study of montelukast for the treatment of respiratory symptoms of post-respiratory syncytial virus bronchiolitis in children.

Authors:  Hans Bisgaard; Alejandro Flores-Nunez; Anne Goh; Parvin Azimi; Andrew Halkas; Marie-Pierre Malice; Jean-Louis Marchal; S Balachandra Dass; Theodore F Reiss; Barbara A Knorr
Journal:  Am J Respir Crit Care Med       Date:  2008-06-26       Impact factor: 21.405

6.  Within-host whole-genome deep sequencing and diversity analysis of human respiratory syncytial virus infection reveals dynamics of genomic diversity in the absence and presence of immune pressure.

Authors:  Yonatan H Grad; Ruchi Newman; Michael Zody; Xiao Yang; Ryan Murphy; James Qu; Christine M Malboeuf; Joshua Z Levin; Marc Lipsitch; John DeVincenzo
Journal:  J Virol       Date:  2014-04-16       Impact factor: 5.103

7.  Respiratory syncytial virus infections in infants: quantitation and duration of shedding.

Authors:  C B Hall; R G Douglas; J M Geiman
Journal:  J Pediatr       Date:  1976-07       Impact factor: 4.406

8.  Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study.

Authors:  John P DeVincenzo; Matthew W McClure; Julian A Symons; Hosnieh Fathi; Christopher Westland; Sushmita Chanda; Rob Lambkin-Williams; Patrick Smith; Qingling Zhang; Leo Beigelman; Lawrence M Blatt; John Fry
Journal:  N Engl J Med       Date:  2015-11-19       Impact factor: 91.245

9.  Strengths and weaknesses of FDA-approved/cleared diagnostic devices for the molecular detection of respiratory pathogens.

Authors:  Christine C Ginocchio
Journal:  Clin Infect Dis       Date:  2011-05       Impact factor: 9.079

Review 10.  Respiratory syncytial virus (RSV) and its propensity for causing bronchiolitis.

Authors:  Raymond J Pickles; John P DeVincenzo
Journal:  J Pathol       Date:  2015-01       Impact factor: 7.996

View more
  9 in total

1.  Respiratory syncytial virus: viral load, viral decay, and disease progression in children with bronchiolitis.

Authors:  Raí André Silva Watanabe; Jessica Santiago Cruz; Luciano Kleber de Souza Luna; Vitória Rodrigues Guimarães Alves; Danielle Dias Conte; Larissa Lyra; Filipe Nishiyama; Bruno Sanchez Camargo; Nancy Bellei
Journal:  Braz J Microbiol       Date:  2022-04-01       Impact factor: 2.214

2.  Haemophilus-Dominant Nasopharyngeal Microbiota Is Associated With Delayed Clearance of Respiratory Syncytial Virus in Infants Hospitalized for Bronchiolitis.

Authors:  Jonathan M Mansbach; Kohei Hasegawa; Pedro A Piedra; Vasanthi Avadhanula; Joseph F Petrosino; Ashley F Sullivan; Janice A Espinola; Carlos A Camargo
Journal:  J Infect Dis       Date:  2019-05-05       Impact factor: 5.226

3.  Viral Load Dynamics and Clinical Disease Severity in Infants With Respiratory Syncytial Virus Infection.

Authors:  Cristina Garcia-Mauriño; Melissa Moore-Clingenpeel; Jessica Thomas; Sara Mertz; Daniel M Cohen; Octavio Ramilo; Asuncion Mejias
Journal:  J Infect Dis       Date:  2019-04-08       Impact factor: 5.226

Review 4.  Role of Type I Interferon (IFN) in the Respiratory Syncytial Virus (RSV) Immune Response and Disease Severity.

Authors:  Diego R Hijano; Luan D Vu; Lawrence M Kauvar; Ralph A Tripp; Fernando P Polack; Stephania A Cormier
Journal:  Front Immunol       Date:  2019-03-26       Impact factor: 7.561

5.  Do asymptomatic respiratory viral infections occur?

Authors:  Ryan H Tomlinson; Lisa G Harrison; Elizabeth A Meals; John P DeVincenzo
Journal:  J Clin Virol       Date:  2018-03-05       Impact factor: 3.168

6.  Risk of Transmission and Viral Shedding From the Time of Infection for Respiratory Syncytial Virus in Households.

Authors:  Hirono Otomaru; Johanna Beulah T Sornillo; Taro Kamigaki; Samantha Louise P Bado; Michiko Okamoto; Mariko Saito-Obata; Marianette T Inobaya; Edelwisa Segubre-Mercado; Portia P Alday; Mayuko Saito; Veronica L Tallo; Beatriz P Quiambao; Hitoshi Oshitani; Alex R Cook
Journal:  Am J Epidemiol       Date:  2021-12-01       Impact factor: 4.897

7.  Factors Contributing to Symptom Duration and Viral Reduction in Outpatient Children With Respiratory Syncytial Virus Infection.

Authors:  Takeshi Utsunomiya; Akinobu Hibino; Kiyosu Taniguchi; Takao Nagai; Naruo Saito; Ikumi Tanabe; Takashi Odagiri; Yugo Shobugawa; Akira Kaneko; Reiko Saito
Journal:  Pediatr Infect Dis J       Date:  2020-08       Impact factor: 3.806

Review 8.  Immunotherapeutic Challenges for Pediatric Cancers.

Authors:  Brian Hutzen; Mohammed Ghonime; Joel Lee; Elaine R Mardis; Ruoning Wang; Dean A Lee; Mitchell S Cairo; Ryan D Roberts; Timothy P Cripe; Kevin A Cassady
Journal:  Mol Ther Oncolytics       Date:  2019-08-28       Impact factor: 7.200

9.  A Randomized, Placebo-Controlled, Respiratory Syncytial Virus Human Challenge Study of the Antiviral Efficacy, Safety, and Pharmacokinetics of RV521, an Inhibitor of the RSV-F Protein.

Authors:  John DeVincenzo; Dereck Tait; John Efthimiou; Julie Mori; Young-In Kim; Elaine Thomas; Lynn Wilson; Rachel Harland; Neil Mathews; Stuart Cockerill; Kenneth Powell; Edward Littler
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.